Advertisement

Annals of Hematology

, Volume 96, Issue 5, pp 787–796 | Cite as

Allogeneic hematopoietic stem cell transplantation for non-Hodgkin’s lymphomas: a retrospective analysis of 77 cases

  • Ana M. Picleanu
  • Silvana Novelli
  • Anna Monter
  • Irene Garcia-Cadenas
  • Ana C. Caballero
  • Rodrigo Martino
  • Albert Esquirol
  • Javier Briones
  • Jorge Sierra
Original Article

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a therapeutic option for relapsed, advanced, and otherwise incurable non-Hodgkin’s lymphomas (NHL) suggested by the existence of a graft-versus-lymphoma effect. The main complications are graft-versus-host disease and infections. We performed a retrospective analysis of patients with NHL, who received an allo-SCT between January 1995 and December 2014. The parameters that had an impact on overall survival were age ≤60 years old, chemosensitive disease pre-allo-SCT, and indolent NHL histology. The parameters that had an impact on progression-free survival were age ≤60 years old and chemosensitive disease pre-allo-SCT. Only aggressive NHL histology and refractory disease pre-allo-SCT showed an increased risk of death in the multivariate model. The use of allo-SCT for young patients with multiple relapsed chemosensitive indolent NHL is a suitable option. Despite poor prognosis, young aggressive NHL patients can be considered for allo-SCT provided they have chemosensitive disease.

Keywords

Hematopoietic stem cell transplantation Allo-SCT Non-Hodgkin’s lymphoma 

Notes

Acknowledgements

This study was supported in part by grants AGAUR 2014SGR-1281 and ISCIII RD12/0036/0071 and a grant from Cellex Research Foundation, Barcelona, Spain.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Novelli S, Sierra J, Briones J (2015) New therapies in non-Hodgkin lymphoma. Expert Rev Anticancer Ther 15(3):349–359. doi: 10.1586/14737140.2015.1002773 CrossRefPubMedGoogle Scholar
  2. 2.
    Aldoss I, Nademanee A (2015) Allogeneic hematopoietic cell transplantation in non-Hodgkin’s lymphomas. Cancer Treat Res 165:329–344. doi: 10.1007/978-3-319-13150-4_14 CrossRefPubMedGoogle Scholar
  3. 3.
    van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR, Chaekal OK, Gale RP, Klein JP, Lazarus HM, McCarthy PL Jr, Raemaekers JM, Reiffers J, Phillips GL, Schattenberg AV, Verdonck LF, Vose JM, Horowitz MM (1998) Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92(5):1832–1836PubMedGoogle Scholar
  4. 4.
    Boeckh M, Murphy WJ, Peggs KS (2015) Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow Transplant. 21(1):24–29. doi: 10.1016/j.bbmt.2014.11.002 CrossRefPubMedGoogle Scholar
  5. 5.
    García-Cadenas I, Castillo N, Martino R, Barba P, Esquirol A, Novelli S, Orti G, Garrido A, Saavedra S, Moreno C, Granell M, Briones J, Brunet S, Navarro F, Ruiz I, Rabella N, Valcárcel D, Sierra J (2015) Impact of Epstein-Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab. Bone Marrow Transplant 50(4):579–584. doi: 10.1038/bmt.2014.298 CrossRefPubMedGoogle Scholar
  6. 6.
    Harrison N, Mitterbauer M, Tobudic S, Kalhs P, Rabitsch W, Greinix H, Burgmann H, Willinger B, Presterl E, Forstner C (2015) Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study. BMC Infect Dis 15:584. doi: 10.1186/s12879-015-1329-6 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Teshima T, Reddy P, Zeiser R (2016) Acute graft-versus-host disease: novel biological insights. Biol Blood Marrow Transplant. 22(1):11–16. doi: 10.1016/j.bbmt.2015.10.001 CrossRefPubMedGoogle Scholar
  8. 8.
    Jones RJ, Ambinder RF, Piantadosi S, Santos GW (1991) Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77(3):649–653PubMedGoogle Scholar
  9. 9.
    Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M, Verneris M, Wagner J, Dusenbery K, Aurora M, Bachanova V, Brunstein C, Burns L, Cooley S, Kaufman D, Majhail NS, McClune B, McGlave P, Miller J, Oran B, Slungaard A, Vercellotti G, Weisdorf DJ (2011) Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant 17(7):1025–1032. doi: 10.1016/j.bbmt.2010.10.030 CrossRefPubMedGoogle Scholar
  10. 10.
    Bloor AJ, Thomson K, Chowdhry N, Verfuerth S, Ings SJ, Chakraverty R, Linch DC, Goldstone AH, Peggs KS, Mackinnon S (2008) High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 14(1):50–58CrossRefPubMedGoogle Scholar
  11. 11.
    Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912–2919CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Barba P, Piñana JL, Martino R, Valcárcel D, Amorós A, Sureda A, Briones J, Delgado J, Brunet S, Sierra J (2010) Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut-off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI is the best predictor of NRM and OS in a population of patients undergoing allo-RIC. Biol Blood Marrow Transplant. 16(3):413–420. doi: 10.1016/j.bbmt.2009.11.008 CrossRefPubMedGoogle Scholar
  13. 13.
    Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T, Dini G, Rocha V, Passweg J, Sureda A, Tichelli A, Niederwieser D, European Group for Blood and Marrow Transplantation and the European Leukemia Net (2009) Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 115(20):4715–4726. doi: 10.1002/cncr.24531 CrossRefPubMedGoogle Scholar
  14. 14.
    Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRefPubMedGoogle Scholar
  15. 15.
    Hamadani M, Benson DM, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM (2009) Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant. 15:547–553. doi: 10.1016/j.bbmt.2009.01.010 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Bishop MR, Dean RM, Steinberg SM et al (2010) Correlation of pretransplant and early posttransplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin’s lymphoma. Cancer 116:852–862CrossRefPubMedGoogle Scholar
  17. 17.
    Fuerst D, Mueller C, Beelen DW, Neuchel C, Tsamadou C, Schrezenmeier H, Mytilineos J (2016) Time-dependent effects of clinical predictors in unrelated hematopoietic stem cell transplantation. Haematologica. 241–247. Doi: 10.3324/haematol.2015.130401
  18. 18.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) Malignant lymphoma. J Clin Oncol 25:579–586CrossRefPubMedGoogle Scholar
  19. 19.
    Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD (2014) The role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas. Imaging Working Group J Clin Oncol 32(27):3048–3058Google Scholar
  20. 20.
    Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 17:1244–1253CrossRefPubMedGoogle Scholar
  21. 21.
    Loiseau P, Busson M, Balere ML, Dormoy A, Bignon JD, Gagne K, Gebuhrer L, Dubois V, Jollet I, Bois M, Perrier P, Masson D, Moine A, Absi L, Reviron D, Lepage V, Tamouza R, Toubert A, Marry E, Chir Z, Jouet JP, Blaise D, Charron D, Raffoux C (2007) HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant. 13(8):965–974CrossRefPubMedGoogle Scholar
  22. 22.
    Wisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C, Setterholm M, Drexler R, Maiers M, King R, Confer D, Klein J (2008) Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 14(7):748–758. doi: 10.1016/j.bbmt.2008.04.003 CrossRefGoogle Scholar
  23. 23.
    Luz LL, Azevedo AM, Mattos IE (2014) Non-Hodgkin’s lymphoma: five-year survival in a historical cohort of patients who underwent stem cell transplantation in Brazil. Revista Brasileira de Cancerologia 60(1):35–42Google Scholar
  24. 24.
    Kim SW, Tanimoto TE, Hirabayashi N et al (2006) Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 108:382–389CrossRefPubMedGoogle Scholar
  25. 25.
    Doocey RT, Toze CL, Connors JM et al (2005) Allogeneic hematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131:223–230CrossRefPubMedGoogle Scholar
  26. 26.
    Khouri IF, McLaughlin P, Saliba RM et al (2008) Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111:5530–5536. doi: 10.1182/blood-2008-01-136242 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Rezvani AR, Storer B, Maris M et al (2008) Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin’s lymphoma. J Clin Oncol 26:211–217CrossRefPubMedGoogle Scholar
  28. 28.
    Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda A, Smith SM, Hamadani M (2016) Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol 174(2):235–248. doi: 10.1111/bjh.14046 CrossRefPubMedGoogle Scholar
  29. 29.
    Robinson SP, Boumendil A, Finel H, Schouten H, Ehninger G, Maertens J, Crawley C, Rambaldi A, Russell N, Anders W, Blaise D, Yakoub-Agha I, Ganser A, Castagna L, Volin L, Cahn JY, Montoto S, Dreger P (2016) Reduced-intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable, long term disease control. An analysis from the Lymphoma Working Party Of the EBMT. Ann OncolGoogle Scholar
  30. 30.
    Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG, Niederwieser D, Chauncey TR, Forman SJ, Agura E, Leis JF, Bruno B, Langston A, Pulsipher MA, McSweeney PA, Wade JC, Epner E, Bo Petersen F, Bethge WA, Maloney DG, Storb R (2007) Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 110(7):2744–2748CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Armand P, Kim HT, Sainvil MM, Lange PB, Giardino AA, Bachanova V, Devine SM, Waller EK, Jagirdar N, Herrera AF, Cutler C, Ho VT, Koreth J, Alyea EP, McAfee SL, Soiffer RJ, Chen YB, Antin JH (2016) The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol 173(1):96–104. doi: 10.1111/bjh.13931 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Hematology DepartmentHospital FilantropiaCraiovaRomania
  2. 2.Hematology Department, Hospital de la Santa Creu i Sant Pau, José Carreras Leukemia Research Institute and IIB Sant PauUniversitat Autònoma de BarcelonaBarcelonaSpain

Personalised recommendations